158 related articles for article (PubMed ID: 29337597)
1. Hydroxyurea for lifelong transfusion-dependent β-thalassemia: A meta-analysis.
Algiraigri AH; Wright NAM; Paolucci EO; Kassam A
Pediatr Hematol Oncol; 2017 Nov; 34(8):435-448. PubMed ID: 29337597
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea for hemoglobin E/β-thalassemia: a systematic review and meta-analysis.
Algiraigri AH; Kassam A
Int J Hematol; 2017 Dec; 106(6):748-756. PubMed ID: 28786080
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea for nontransfusion-dependent β-thalassemia: A systematic review and meta-analysis.
Algiraigri AH; Wright NAM; Paolucci EO; Kassam A
Hematol Oncol Stem Cell Ther; 2017 Sep; 10(3):116-125. PubMed ID: 28408107
[TBL] [Abstract][Full Text] [Related]
4. The effect and side effect of hydroxyurea therapy on patients with β-thalassemia: a systematic review to December 2012.
Kosaryan M; Zafari M; Alipur A; Hedayatizadeh-Omran A
Hemoglobin; 2014; 38(4):262-71. PubMed ID: 25023087
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of hydroxyurea (HU) in reduction of pack red cell (PRC) transfusion requirement among children having beta-thalassemia major: Karachi HU trial (KHUT).
Ansari SH; Shamsi TS; Siddiqui FJ; Irfan M; Perveen K; Farzana T; Panjwani VK; Yousuf A; Mehboob T
J Pediatr Hematol Oncol; 2007 Nov; 29(11):743-6. PubMed ID: 17984691
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic superiority and safety of combined hydroxyurea with recombinant human erythropoietin over hydroxyurea in young β-thalassemia intermedia patients.
Elalfy MS; Adly AA; Ismail EA; Elhenawy YI; Elghamry IR
Eur J Haematol; 2013 Dec; 91(6):522-33. PubMed ID: 23927461
[TBL] [Abstract][Full Text] [Related]
7. Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.
Mtvarelidze Z; Kvezereli-Kopadze A; Kvezereli-Kopadze M; Mestiashvili I
Georgian Med News; 2008 Mar; (156):91-4. PubMed ID: 18403819
[TBL] [Abstract][Full Text] [Related]
8. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India.
Jain M; Chakrabarti P; Dolai TK; Ghosh P; Mandal PK; Baul SN; De R
Blood Cells Mol Dis; 2021 May; 88():102544. PubMed ID: 33610115
[TBL] [Abstract][Full Text] [Related]
9. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
Kosaryan M; Karami H; Zafari M; Yaghobi N
Hemoglobin; 2014; 38(2):115-8. PubMed ID: 24471558
[TBL] [Abstract][Full Text] [Related]
10. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
11. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
El-Beshlawy A; El-Ghamrawy M; EL-Ela MA; Said F; Adolf S; Abdel-Razek AR; Magdy RI; Abdel-Salam A
Ann Hematol; 2014 Dec; 93(12):2045-50. PubMed ID: 25062719
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience.
Karimi M; Zarei T; Bahmanimehr A; Aramesh A; Daryanoush S; Haghpanah S
Ann Hematol; 2021 Dec; 100(12):2901-2907. PubMed ID: 34383102
[TBL] [Abstract][Full Text] [Related]
13. Response to hydroxyurea therapy in beta-thalassemia.
Koren A; Levin C; Dgany O; Kransnov T; Elhasid R; Zalman L; Palmor H; Tamary H
Am J Hematol; 2008 May; 83(5):366-70. PubMed ID: 18181203
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea in the management of thalassemia intermedia.
Karimi M
Hemoglobin; 2009; 33 Suppl 1():S177-82. PubMed ID: 20001623
[TBL] [Abstract][Full Text] [Related]
15. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.
Karimi M; Haghpanah S; Farhadi A; Yavarian M
Int J Hematol; 2012 Jan; 95(1):51-6. PubMed ID: 22180324
[TBL] [Abstract][Full Text] [Related]
16. Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the
Ghosh D; Panja A; Saha D; Banerjee U; Datta AK; Basu A
Genet Test Mol Biomarkers; 2021 Aug; 25(8):563-570. PubMed ID: 34406845
[No Abstract] [Full Text] [Related]
17. Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.
Bhurani D; Kapoor J; Yadav N; Khushoo V; Agrawal N; Ahmed R; Arora JS; Mehta P
Ann Hematol; 2021 Jun; 100(6):1417-1427. PubMed ID: 33811502
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.
Bradai M; Abad MT; Pissard S; Lamraoui F; Skopinski L; de Montalembert M
Blood; 2003 Aug; 102(4):1529-30. PubMed ID: 12702505
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.
Ansari SH; Shamsi TS; Ashraf M; Perveen K; Farzana T; Bohray M; Erum S; Mehboob T
J Pediatr Hematol Oncol; 2011 Jul; 33(5):339-43. PubMed ID: 21602718
[TBL] [Abstract][Full Text] [Related]
20. Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion.
Ansari SH; Shamsi TS; Munzir S; Khan MT; Erum S; Perveen K; Farzana T; Ashraf M; Mehboob T; Moinuddin M
J Pediatr Hematol Oncol; 2013 May; 35(4):e153-6. PubMed ID: 23389500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
